HBV pgRNA drives chronic inflammation in CHB patients by inducing IL-1β in neutrophils
Background
Despite advancements in antiviral therapies like nucleoside analogs (NAs), Chronic Hepatitis B (CHB) remains a significant global health burden, often progressing to cirrhosis and hepatocellular carcinoma. A key gap in understanding CHB pathogenesis is the role of viral components beyond canonical proteins in driving chronic inflammation. While HBV pregenomic RNA (pgRNA) is known as a marker of viral transcriptional activity, its direct involvement in modulating innate immunity and contributing to the persistent inflammatory state in CHB patients has been poorly understood, representing a critical area for investigation to identify novel therapeutic targets.
Study Design
Researchers enrolled a cohort of 88 patients with CHB who were receiving nucleoside analogs (NAs). For a deeper mechanistic dive, samples from 8 HBeAg-negative CHB patients (4 positive for HBV pgRNA, 4 negative) underwent transcriptomic analysis. Bioinformatic tools identified common pathways, leading to experimental setups investigating platelet activation and platelet-neutrophil interactions. The study also examined the synthesis and expression of key inflammatory interleukins, specifically IL-1β, IL-17A, and the antimicrobial peptide LL-37, to elucidate the innate immune response triggered by HBV pgRNA.
Results
HBV pgRNA was detected in 18.1% of the total study population. Transcriptomic analysis of pgRNA-positive versus pgRNA-negative patients revealed common differentially expressed genes primarily involved in platelet activation and neutrophil degranulation pathways. Further experimental validation showed that platelets stimulated with HBV pgRNA-positive serum exhibited induced autophagy and de novo synthesis of the peptide LL-37. Crucially, a combined study of platelet-neutrophil interactions demonstrated a pronounced proinflammatory phenotype, characterized by significantly high levels of IL-1β in neutrophils, which was accompanied by minimal NET formation. This suggests a specific, IL-1β-dependent inflammatory axis.
Platelets stimulated with HBV pgRNA-positive serum showed induction of
autophagyand de novo synthesis of the peptide LL-37, indicating a direct role for pgRNA in cellular responses.
Key Findings
- HBV pgRNA was detected in 18.1% of CHB patients receiving nucleoside analogs.
Transcriptomic analysisidentifiedplatelet activationandneutrophil degranulationpathways in pgRNA-positive patients.- HBV pgRNA-positive serum induced
autophagyandLL-37synthesis in platelets. - Platelet-neutrophil interactions with pgRNA-positive serum led to high
IL-1βlevels in neutrophils. - A proinflammatory phenotype was observed, characterized by
IL-1βinduction and minimalNET formation.
Why It Matters
This research significantly advances our understanding of CHB pathogenesis, highlighting HBV pgRNA as a direct driver of inflammation, rather than just a viral activity marker. For clinicians, this suggests that monitoring pgRNA levels could serve as a prognostic indicator for inflammatory burden, even in patients on NAs. It opens avenues for developing adjunctive anti-inflammatory therapies targeting IL-1β or platelet activation pathways, potentially improving outcomes beyond current antiviral strategies. Identifying pgRNA's role in innate immunity provides a novel therapeutic target to mitigate chronic inflammation in CHB, moving towards more personalized and comprehensive treatment approaches for patients who continue to experience inflammation despite viral suppression.
hbv
chronic-hepatitis-b
inflammation
il-1beta
ll-37
innate-immunity